- Accelerates the transformation of solventum business and sharpens focuses on strategic areas for growth to provide long -term shareholder value
- Strengthens balance with income to be used mainly for debt payments
Str. Paul, Minn., 25 February 2025 / Prnewswire/ – Solventum (NYSE: Solv) announced today that it has entered a final agreement to sell its cleaning and filtering1 Business at Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher“) for $ 4.1 billion. Solventum expects the transaction to be neutral for 2025 EPS and expects an estimate $ 3.4 billion In net income, which aims to use mainly to pay debt. The transaction is expected to be completed by the end of 2025, subject to regulatory approval and customary closure conditions.
“The sale of the cleaning and filtering business is part of the third phase of our transformation plan and follows a thorough analysis of our business strategic value and approximation,” he said Bryan HansonCEO Solventum. “This transaction will improve our strategic focus and main meters by reducing the lever and significantly strengthening our balance. It also enables us to invest in the innovation, programs and talent we need to execute our mission and offer shareholder value. “
Mr. Hanson continued, “Solventum is committed to providing a smooth transition for employees, customers and other stakeholders, and we are confident that Thermo Fisher will provide the cleaning and filtering business – which offers filters and membranes for use in the production of biofarmic and medical technologies, microelectronics and food, beverage products and drinking water – strategic investments and resources needed to maintain growth and delivery client solutions. “
Solventum will discuss the transaction in its fourth quarter and full 2024 call of planned profits 27 February 2025. With this significant change in the company’s portfolio and other major actions taken since he became a publicly traded independent company in 1 April 2024Treventum has planned an investor day March 20, 2025To provide investors with an update over the progress made, its positioning forward and the long -range plan. Investor’s day will be held at New York CityAnd the company will share additional logistical details in a timely manner.
Morgan Stanley & Co. LLC, Perella Weinberg Partners and JP Morgan Securities LLC served as Financial Advisors for Solventum, and Cleary Gottlieb Steen & Hamilton served as a legal adviser in Solventum.
1In addition to its operations in Belgium, France AND Irelandto which Thermo Fisher gave a bidding bid solventum
Around
In Solventum, we enable better, smarter, safer health care to improve life. As a new company with a long legacy for creating progress solutions for the most difficult challenges of our clients, we pioneer the innovations that change the game at the intersection of health, material and data science that change the life of patients for better -When we empower health care professionals to perform to their maximum. See as on solventum.com.
Future statements
This news announcement contains future information about solventum financial results, business assessments and prospects that include significant risks and uncertainty. In particular, statements regarding the future solventtum performance, including guidelines for 2024, are future statements. You can identify these statements with the use of words such as “predicts”, “believes”, “can”, “values”, “waits”, “forecasts”, “outlook”, “plans”, “projects “,” Requires “,” See “,” Must “,” Goals “Future Discussion Operational or Financial Performance or Business Plans or Perspectives. These: (1) Effects and changes in economic, political, regulatory, international, international, commercial and geopolitical conditions, natural disasters, war, public health crises, and public health crises, and other events beyond the control of Solventum; other strategic; (7) exposure to the interest rate and currency risks; (8) highly competitive environment in which solvent and consolidation in the health care industry operates; (9) reducing customer research budgets or government funds; (10) Time and acceptance of the new bids market of product and solventum services; (11) continued working relationship with some key health care professionals; (12) changes in reimbursement practices of government or private payers or other cost control measures; (13) Solventum’s ability to obtain components or raw materials supplied by third parties and other manufacturing and linked to the supply chain, disruption and divisive factors; (14) Legal and Regulatory Procedures and Risks of Legal Compliance (including third party risks) on antitrust, law of foreign corruption practices (FCPA) and other anti -bribe laws, environmental laws, laws and requirements fake, privacy laws, tax laws and other laws and regulations in United States and other countries in which it operates Treventum; (15) possible obligations regarding a wide group of perfluoroalkyl and polyfluoroalkil substances, collectively known as “PFAS”; (16) Risks associated with the highly regulated environment in which it operates three; (17) risks associated with claims of product responsibility; (18) climate change and measures to address climate change; (19) security violations and other interruptions in information technology infrastructure; (20) non -collection of solventum to obtain, maintain, protect, or effectively its intellectual property rights (“IP”); (21) Pension obligations and posstrethyent; (22) any failure from 3m Company (”3m“) to perform any of its obligations according to the various division agreements with respect to the separation from 3m (“spin-off”); (23) Any failure to realize the expected benefits of spin-off, and/or that spin-off will not end within the expected time frame, with the expected or not at all; (24) a determination by the IRS or other tax authorities that certain distribution or related transactions must be treated as taxable transactions; (25) expected financing transactions undertaken in relation to division and risks associated with additional debt; (26) the risk that the additional costs of functioning on an independent basis (including loss of synergies), the costs of restructuring transactions and other costs made with respect to the division will exceed solventum estimates; and (27) the impact of spin-off on its businesses and the risk that spin-off may be more difficult, requires time or costly than expected, including the impact on its resources, systems, procedures and controls, deviation and attention of management and impact on relationships with clients, suppliers, employees and other business parties.
Changes in such assumptions or factors can produce significantly different results. A further description of these factors is placed under “Note Care in relation to future statements” and “risk factors” in periodic solventum reports in the file with the US Insurance and Exchange Commission. Solventum receives no obligation to update any future statement discussed here as a result of new information or future events or developments.
Solvent